Central pharmacokinetics of levodopa: Lessons from imaging studies

Movement Disorders

Volumn 30, Issue 1, 2015, Pages 73-79

  Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dopamine; Dopamine release; Dopamine transporter; Dopamine turnover; Positron emission tomography; Serotonin

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; LEVODOPA; NEUROTRANSMITTER; RADIOLIGAND; TRACER; ANTIPARKINSON AGENT;

DOPAMINE RELEASE; DYSKINESIA; FUNCTIONAL NEUROIMAGING; GLUCOSE METABOLISM; HUMAN; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TURNOVER TIME; BRAIN; DRUG EFFECTS; SCINTISCANNING;

ANTIPARKINSON AGENTS; BRAIN; HUMANS; LEVODOPA; POSITRON-EMISSION TOMOGRAPHY;

EID: 84920771791     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26046     Document Type: Review

References (35)

1. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
2. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 2011;134:3290-3298.
3. Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18 F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
4. Colloby SJ, McParland S, O'Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain 2012;135:2798-2808.
5. Yee RE, Irwin I, Milonas C, et al. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord 2001;16:838-848.
6. Karimi M, Tian L, Brown CA, et al. Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 2013;73:390-396.
7. Piccini P, Pavese N, Brooks DJ. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 2003;53:647-653.
8. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303.
9. Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11 C] raclopride displacement and PET. Neurology 1996;46:1430-1436.
10. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990;525:36-44.
11. Thobois S, Vingerhoets F, Fraix V, et al. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch Neurol 2004;61:1705-1709.
12. Scherfler C, Khan NL, Pavese N, et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 2004;127:1332-1342.
13. Scherfler C, Khan NL, Pavese N, et al. Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. Mov Disord 2006;21:783-788.
14. Kaasinen V, Ruottinen HM, Nagren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11 C]raclopride and [11 C]N-methylspiperone. J Nucl Med 2000;41:65-70.
15. Seeman P, Guan HC, Niznik HB. Endogenous dopamine lowers the dopamine D 2 receptor density as measured by 3 H raclopride: implications for positron emission tomography of the human brain. Synapse 1989;3:96-97.
16. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000;20:423-451.
17. Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:718-723.
18. Luquin MR, Vaamonde J, Obeso JA. Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response. Clin Neuropharmacol 1989;12:46-54.
19. de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127:2747-2754.
20. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006;67:1612-1617.
21. de la Fuente-Fernandez R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 2011;69:803-810.
22. Doudet DJ, Chan GLY, Holden JE, et al. Effects of monoamine oxidase and catechol- O -methyltransferase inhibition on dopamine turnover: a PET study with 6-[18 F]L-DOPA. Eur J Pharmacol 1997;334:31-38.
23. Doudet DJ, Chan GLY, Holden JE, et al. 6-[18 F]Fluoro-L-dopa PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998;29:225-232.
24. Sossi V, Doudet DJ, Holden JE. A reversible tracer analysis approach to the study of effective dopamine turnover. J Cereb Blood Flow Metab 2001;21:469-476.
25. Sossi V, Fuente-Fernandez R, Schulzer M, Adams J, Stoessl J. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 2006;129:1050-1058.
26. Sossi V, Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 2007;62:468-474.
27. Troiano AR, Fuente-Fernandez R, Sossi V, et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009;72:1211-1216.
28. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130:1819-1833.
29. Politis M, Wu K, Loane C, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2010;2:38-46.
30. Politis M, Wu K, Loane C, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest 2014;124:1340-1349.
31. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852-858.
32. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009;132:1376-1385.
33. O'Sullivan SS, Wu K, Politis M, et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011;134:969-978.
34. Ahmad R, Bourgeois S, Postnov A, et al. PET imaging shows loss of striatal PDE10A in patients with Huntington disease. Neurology 2014;82:279-281.
35. Sander CY, Hooker JM, Catana C, et al. Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proc Natl Acad Sci U S A 2013;110:11169-11174.